Editas Medicine Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Editas Medicine's estimated annual revenue is currently $25.1M per year.
- Editas Medicine received $50.0M in venture funding in December 2017.
- Editas Medicine's estimated revenue per employee is $155,000
- Editas Medicine has 162 Employees.
- Editas Medicine grew their employee count by 5% last year.
- Editas Medicine currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Editas Medicine?
Unlocking the Promise of Genome Editing to Deliver Life-Changing Medicines. As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Editas Medicine News
The recent performance of Editas Medicine (NASDAQ:EDIT) stock in the market spoke loud and clear to investors as EDIT saw more than ...
CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today ...
On Friday the shares-rate of the Company Editas Medicine, EDIT Stock exchange NASDAQ, is an exciting player in the Medical.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Editas Medicine Funding
Editas Medicine Executive Hires
|2015-04-28||Vic Myer||Chief Technology Officer||Article|
|2016-01-06||Timothy D. Hunt||SVP Corporate Affairs||Article|